Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harborin… Recruiting

2023-505662-28-00 Non-small-cell lung cancer stages I B, II and selected 4 2024-10-30
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects … Recruiting

2023-505334-10-01 Unresectable, Locally Advanced, or Metastatic Solid Tum 7 2024-10-30
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
The BLESS Trial Recruiting

2024-513360-25-00 Any cancer with cutaneous malignancies 11 2024-10-29
Small patient study to explore the anticancer effect of cannabis oil in untreatable patients with liver cancer Recruiting

2024-514049-13-02 Patients with untreatable hepatocellulare carcinoma 4 2024-10-29
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Metastatic colorectal cancer 5 2024-10-28
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies Recruiting

2024-511453-22-00 Participants with Advanced Solid Malignancies 1 2024-10-28
Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preferenc… Recruiting

2023-509465-20-00 metastatic pancreatic cancer 5 2024-10-28
Preventing liver recurrence after partial hepatectomy for intrahepatic cholangiocarcinoma using adjuvant hepatic arterial infusion pump chem… Recruiting

2024-513726-33-00 Intrahepatic cholangiocarcinoma (iCCA) 4 2024-10-25
not applicable Recruiting

2023-508953-16-00 Newly diagnosed high grade glioma (HGG) including diffu 4 2024-10-25
Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide Recruiting

2024-511026-31-01 Glioblastoma grade 4 4 2024-10-24
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
CAR123 T cell treatment of relapsed/refractory hematologic malignancies. Recruiting

2022-503165-30-00 Relapsed/refractory CD123+ hematological malignancies: 1 2024-10-23
New Beacon Recruiting

2024-518419-20-00 BRAF V600E mutated colorectal cancer 4 2024-10-23
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leu… Recruiting

2023-503394-37-00 Acute Myeloid Leucaemia 5 2024-10-23
study of pembrolizumab in classic or endemic Kaposi’s sarcoma Recruiting

2024-514241-10-00 Kaposi's sarcoma 4 2024-10-22
A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting

2023-509851-15-00 Colon cancer 5 2024-10-22
Local Levobupivacaine for pain reflief after esophageal ESD Recruiting

2024-510912-66-00 Visible esophageal lesions ((pre)cancerous) 6 2024-10-22
Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting

2023-510429-14-00 HER2-mutated or overexpressed/amplified solid tumours 4 2024-10-22
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or meta… Recruiting

2024-514875-16-00 First-line treatment of PD-L1-positive recurrent or met 4 2024-10-21
Artificial Intelligence driven personalisation of radiotherapy and concomitant androgen deprivation therapy for prostate cancer patients Recruiting

2024-510707-11-00 Prostate cancer 4 2024-10-21
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting

2023-509334-19-00 gastro-enteropancreatic neuroendocrine tumors (GEP-NETs 5 2024-10-17
PERi-operative Selective Decontamination of the Digestive tract to prevent severe infectious complications after Esophagectomy: a Randomized… Recruiting

2023-504144-33-01 esophageal cancer 11 2024-10-17